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ABSTRACT 
Objectives: A growing evidence base implicates human cytomegalovirus (HCMV) as a risk factor for 
TB disease. We investigated total IgG and mycobacteria-specific antibodies in a cross-sectional study 
nested within a rural Ugandan General Population Cohort (GPC), in relation to HIV infection and the 
magnitude of HCMV IgG response.  
 
Methods: Sera from 2,189 individuals (including 27 sputum-positive TB cases) were analysed for 
antibodies against mycobacteria (Ag85A, PPD, LAM, ESAT6/CFP10) and HCMV, tetanus toxoid (TT) 
and total IgG.  
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Results: Anti-mycobacterial antibodies increased with age until approximately 20 years, when they 
plateaued. Higher HCMV exposure (measured by IgG) was associated with lower levels of some anti-
mycobacterial antibodies, but no increase in total IgG. HIV infection was associated with a decrease 
in all anti-mycobacterial antibodies measured and with an increase in total IgG.  
Conclusions: The increase in anti-mycobacterial antibodies with age suggests increasing exposure to 
non-tuberculous mycobacteria (NTM), and to M.tb itself. HIV infection is associated with decreased 
levels of all mycobacterial antibodies studied here, and high levels of HCMV IgG are associated with 
decreased levels of some mycobacterial antibodies. These findings point towards the importance of 
humoral immune responses in HIV/TB co-infection and highlight a possible role of HCMV as a risk 
factor for TB disease.  
 
Keywords: TB, HIV, HCMV, Mycobacterium 
 
Introduction 
The role of antibody-mediated immunity in TB has not been fully elucidated (reviewed in [1]). 
Despite the importance of cell-mediated Th1 responses in TB disease [2,3], attempts to stimulate 
this arm of the human immune response by vaccine developers have not translated into protection 
from disease in human efficacy trials [4,5], and there may be useful humoral correlates of disease or 
protection yet to be identified. 
 A growing evidence base for the importance of antibodies in protection against other 
intracellular pathogens such as Listeria monocytogenes [6] and Salmonella spp [7] has led to 
renewed interest in humoral responses to TB and the factors which may affect them. Recent work 
has suggested a potential protective role of antigen 85A (Ag85A)-specific antibodies in reduced TB 
disease risk in BCG-vaccinated South African infants [8,9].  
 It is known that TB and HIV work synergistically to exacerbate morbidity and mortality in co-
infected individuals with respect to both diseases [10]. Epidemiologically, concomitant viral 
infections other than HIV are known to be associated with poor TB outcomes. In Taiwan Hepatitis C 
infection was associated with a higher risk of developing active TB disease [11], and in South Africa 
influenza/TB co-infection was associated with increased mortality [12].  A large TB vaccine trial in 
South Africa, which investigated correlates of TB disease risk or protection, found an association 
between CD8 T-cell activation and HCMV response [8] that was linked to increased risk of TB disease 
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and shorter time to diagnosis [13]. The ubiquitous herpes virus HCMV is known to cause immune 
activation [14], immune senescence [15], and is a significant factor in immune variation [16]. 
Recently, our group has reported elevated levels of HCMV IgG among TB patients compared to 
controls [17].  Despite this, and the findings of some early epidemiologic studies [18,19], data linking 
HCMV and TB are sparse.   
 To investigate mycobacteria-specific antibody levels across ages, and to examine potential 
effects of HCMV co-infection on antibody levels, this study tested 2,187 stored serum samples (of 
which 27 were active TB cases) from a rural Ugandan cohort for IgG responses to Ag85A, purified 
protein derivative (PPD), lipoarabinomannan (LAM) and CFP10/ESAT6, along with IgM responses to 
Ag85A. These antigens were chosen based on availability, evidence of their potential importance in 
TB disease from the literature (Ag85A [9], LAM [20,21], PPD [22]), and specificity to M.tb 
(CFP10/ESAT6 [23]). Seropositivity to HCMV was measured and existing data on HIV, BCG 
vaccination status, as well as demographic information was matched and investigated for 
associations. Responses to tetanus toxoid (TT) and total IgG levels were also investigated as control 
antibodies.  
 
Materials and Methods 
Study area and design 
The General Population Cohort (GPC) is a population-based open cohort study in rural south-
western Uganda, administered by the Medical Research Council (MRC) UK in collaboration with the 
Uganda Virus Research Institute (UVRI) [24]. The cohort comprises a cluster of 25 neighboring 
villages with approximately 20,000 residents (52% aged <13 years) from three ethnic groups, the 
majority (75%) being from the Baganda tribe, the main tribal group in the region. Data are collected 
through an annual census, questionnaire and serological survey (further details on questions 
included in the census can be found in a publication by Asiki. et al [24]). Demographic information 
was collected at the same time as the blood samples. Blood specimens were obtained and 
immediately tested for HIV-1.  Samples with inconclusive results were retested. Remaining sera were 
stored at -80°C. All samples used for this study, except active TB cases, were collected from adults 
and children in GPC round 22, conducted in 2011. Active TB cases were diagnosed through positive 
sputum smear microscopy after passive case detection and were sampled from a range of GPC 
rounds between 1999 and 2014. Sera collected as close as possible to the time of TB diagnosis were 
used for this study (between 5 years prior to, and 0.8 years after, diagnosis of active TB diagnosis). 
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Sampling  
Individuals were selected for inclusion in this cross-sectional study at random after stratification by 
age and sex. Due to anticipated high levels of HCMV seropositivity, infants under the age of 5 were 
oversampled. Individuals were only sampled once and siblings and parent-child pairs were not 
excluded. The total planned sample size was 2,000, plus 10% oversampling.  A target of 
approximately 100 individuals per year of age up to 5 years, 200 individuals aged 6-10, 11-15 and 16-
20, 200 in subsequent ten-year intervals up to 60 years and 200 people aged 61 years or over. The 
sex ratio was approximately equal within each age group (Table 1).  
 
Ethics  
Written consent or assent in conjunction with parental/guardian consent for those younger than 18 
years  were obtained following Uganda National Council of Science and Technology (UNCST) 
guidelines before all survey procedures [24]. Written consent/assent was also obtained from 
participants on the use of their clinical records and stored biological samples for research purposes. 
 Ethical approval for the use of GPC samples for this study was obtained from the UVRI Research 
and Ethics Committee and from the UNCST, in addition to the London School of Hygiene & Tropical 
Medicine (LSHTM), London, UK.  
 
Serology: Ag85A, PPD, LAM, CFP10/ESAT6 and TT 
Antibody content was measured using ELISA. Experimenters were blind to exposure group for all 
samples. Testing was conducted at UVRI in Entebbe, Uganda (Ag85A IgG and PPD IgG) and LSHTM, 
London, UK (CFP10/ESAT6 IgG, Ag85A IgM, LAM IgG and TT IgG). Half volume ELISA plates (Fisher 
Scientific) were coated overnight at 4°C with sodium carbonate buffer containing 1.5µg/mL 
recombinant Ag85A protein (Aeras, USA), 1.5µg/mL PPD (Lot 051815KA, Aeras, USA), 0.5µg/mL TT 
(02/232, NIBSC, UK), 0.5µg/mL LAM (NR-14848, BEI Resources, VA, USA), 0.25ug/mL each CFP10 
(NR-49425, BEI Resources, VA, USA) and ESAT6 (NR-14868, BEI Resources, VA, USA). Plates and 
reagents were brought to room temperature and the plate was washed 3 times with PBS, 5% 
Tween20 (v/v) (PBST). After blocking with PBS 5% milk (w/v) blocking buffer, duplicate 1:100 test 
serum, high and low PPD responder controls and plate blanks consisting of assay diluent alone with 
no serum were added in triplicate. Incubation for 2 hours at room temperature and washing with 
PBST was followed by a one hour incubation with an appropriately diluted peroxidase-conjugated 
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secondary antibody in PBST-5% (IgG, 1:500 dilution of goat anti-human IgG-HRP (04-10-20, KPL, 
USA); IgM, 1:10,000 dilution of goat anti-human IgM-HRP (Abcam ab97205, RRID: AB_10695942)). 
After washing with PBST, 50µL tetramethylbenzidine (TMB, BD BioSciences, USA) was added to each 
well. The plate was incubated for 15 minutes in the dark before the reaction was stopped by adding 
50uL of 2M Sulphuric Acid (Sigma, USA) to each well. Absorbance was measured at 450nm within 30 
minutes to obtain optical density (OD), a surrogate marker of antibody titre. 
 Mean blank values were subtracted from all OD readings, and geometric means of duplicates 
were used to reduce the effect of skewed distribution. Median levels with interquartile ranges (IQR) 
are used for graphical representation of antibody levels in figures 1 and 2.  
 
Total IgG serology 
All samples were tested for total IgG content at LSHTM. As above, half volume ELISA plates were 
coated overnight with mouse anti-human IgG at 0.5ug/mL (Abcam ab200699). IgG antibody 
standards (134.4-8.4 ng/mL) were prepared by diluting purified human IgG (Sigma I4506, 
RRID:AB_1163606) in PSBT-5% milk and test sera were diluted 8x10
5 
in PBST-5% Milk. Duplicate test 
samples, controls and blanks were incubated for one hour at 37°C, and, after washing, samples 
incubated with peroxidase-conjugated goat anti-human Fc (Abcam ab97225, RRID: AB_10680850) 
diluted 1/500 with PBST-5% Milk for one hour at room temperature. Plates were developed with 
TMB, and sulphuric acid was added to stop the reaction. Plates were read at 450nm and OD 
measurements converted into g/L by use of the standard curve on each plate.  
 
Serology HCMV 
Samples were tested for IgG antibodies against HCMV using a commercial ELISA kit (Novatec 
Immunodiagnostica GmbH) according to kit instructions (described in [17]).  
 
Statistical analysis 
Correlations between each pair of mycobacterial antibody OD levels were conducted using 
^ƉĞĂƌŵĂŶ ?ƐƌŚŽ ?Because of the ubiquity of HCMV infection within this population [17], analysis was 
conducted on the HCMV-seropositive population only.  
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 Individuals seropositive for HCMV IgG were further categorized into 3 groups according to 
tertiles of HCMV antibody concentrations (measured by OD): low, medium and high. 
 Linear regression was used to determine the association of each antibody response (as 
continuous dependent variables) with HCMV IgG tertile and HIV infection (as independent variables 
with HCMV as a categorical variable), adjusting for age and sex. BCG vaccination status and active TB 
disease were also included in the regression model, however as 89% (24/27) of active TB cases had 
unknown BCG status, it was not possible to include both variables in the same model. The model 
including TB was preferred, with the model including BCG run as a comparison to confirm the 
consistency of the results. BCG vaccination was included in a separate regression analysis using the 
same model.  
 Individuals with unknown HIV status were excluded from all regression analyses and individuals 
with unknown BCG vaccination status were excluded from regression analyses including BCG. To 
account for evidence of non-linearity of antibody OD with age (likelihood ratio test p<0.001 for all 
antibodies), a quadratic term for age was included in the regression analyses. Numbers included in 
each of the regression analyses are shown in Tables 2 and 3.  
 To account for multiple comparisons, 99% confidence intervals (CIs) are reported and a p value 
of 0.01 was considered to represent strong evidence to reject the null hypothesis. Due to different 
dynamic ranges of spectrophotometers used in Uganda and the UK, antibody OD measurements (for 
mycobacterial antibodies only) were rescaled, or normalized, for graphical representation. This was 
done by subtracting the minimum value within the range from each value, dividing by the range for 
that antibody and multiplying by 100; hence Figure 1 shows the percentage of the maximum OD. All 
analyses were performed on raw (non-normalized) data using Stata version 14 (Stata Corporation, 
College Station, TX, USA). Anonymised participant data are available. 
 
Results 
Sera were sampled from 2,189 individuals. Total IgG levels could not be determined in 15 instances, 
likely due to protein degradation. Of the remaining 2,174 individuals, 8.6% (186/2,174) were HCMV-
seronegative and were excluded from analysis. The HCMV-negative population contained no TB 
cases and 4 HIV-positive individuals.  98 (53%) were female and the mean age was 14.6 years (range 
3 months-95 years). 
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 The remaining 1,988 individuals were included in further analyses. The mean age was 23.4 years 
(range 30 days-100 years) and 50% were female (Table 1). Ninety-eight percent (1,956/1,988) of 
individuals had a conclusive HIV result, and of those, 4.9% (96/1,956) were HIV-positive, with the 
greatest proportion in the 31-50 year age group.  
 Twenty-seven sputum-confirmed TB cases were included in the study, of whom 63% (17/27) 
were female and whose mean age was 36 years (range 12-59 years). Only three TB cases had BCG 
vaccination information and all of those were unvaccinated. All 27 were HCMV-seropositive, with 
59% (16/27) having HCMV IgG levels in the upper tertile.  
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Table 1. Characteristics of study participants (HCMV seropositive individuals by age group 
(N=1,988)). Sex, HIV infection, BCG vaccination and TB case prevalence is shown for each age group.  
Age 
group 
(yr) 
N Sex (percentage 
female 
(number/total)) 
HIV prevalence, 
percentage 
(number/total) 
BCG vaccinated, 
percentage 
(number/total) 
Active TB cases, 
percentage 
(number/total) 
      
<1 75 47% (35/75) 4% (3/73) 76% (54/71) 0% (0/75) 
1 83 51% (42/83) 1% (1/80) 96% (73/76) 0% (0/83) 
2 82 52% (43/82) 1% (1/78) 90% (63/70) 0% (0/82) 
3 87 47% (41/87) 1% (1/85) 93% (70/75) 0% (0/87) 
4 100 52% (52/100) 0% (0/97) 94% (82/87) 0% (0/100) 
5 106 54% (57/106) 1% (1/101) 8% (80/90) 0% (0/106) 
6-10 183 47% (86/183) 1% (2/175) 90% (135/150) 0% (0/183) 
11-15 192 49% (94/192) 0% (0/187) 81% (125/155) 1% (1/192) 
16-20 204 51% (105/204) 1% (3/204) 69% (132/190) 0.5% (1/204) 
21-30 216 56% (120/216) 9% (19/216) 70% (128/184) 2% (5/216) 
31-40 238 52% (123/238) 13% (31/238) 57% (119/209) 4% (10/238) 
41-50 166 45% (74/166) 15% (25/166) 52% (75/145) 4% (6/166) 
51-60 109 49% (53/109) 6% (7/109) 53% (52/98) 4% (4/109) 
61+ 147 46% (68/147) 1% (2/147) 26% (37/144) 0% (0/147) 
Total  1,988 50% (993/1,988) 5% (96/1,956) 70% (1,225/1,744) 1.4% (27/1,988) 
 
 
Antibody responses  
IgG against Ag85A, PPD, LAM, CFP10/ESAT6 and IgM against Ag85A all increased from birth to 
approximately 20 years of age, after which OD values reached a plateau. Figure 1 shows median OD 
for each of the mycobacterial antibody levels by age group. Initial levels in infants under the age of 
one year range from a median of 4% of maximum OD (0.12 OD) for Ag85A IgM to 12% of maximum 
OD (0.35 OD) for LAM IgG. Responses to the M.tb-specific ESAT6/CFP10 antigens did not show the 
same rapid increase from birth as responses to other mycobacterial antibodies. The highest 10% of 
responders in terms of CFP10/ESAT6, being M.tb specific antigens, were investigated further and 
there was no evidence of a difference in proportion of TB cases or HIV positive individuals compared 
the lowest 10%.  
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 Univariate analysis showed no differences in mean OD levels by sex. Analysis of correlation 
showed a high degree of co-linearity between all mycobacterial antibodies (0.33>rho<0.65, all 
p<0.001). OD ranged from 0.002-1.793 OD for Ag85A IgG, 0.000-1.930 OD for PPD IgG, 0.004-2.961 
OD for LAM IgG, 0.005-2.927 OD for CFP10/ESAT6 IgG and 0.001-2.926 OD for Ag85A IgM.  
 
Figure 1. Median mycobacterial antibody OD by age group.  Vertical lines show IQR for median 
values for each age group. Total n= 1,988. OD values rescaled to percentage of maximum for 
graphical representation. IQR  ? interquartile range, OD  ? optical density. 
 
TT and total IgG levels were investigated as control antibodies (Figure 2). TT vaccination induces high 
levels of TT IgG and is given at birth and to pregnant females as part of the Uganda immunization 
schedule [25]. TT IgG showed high levels of antibody from birth and a clear sex difference with 
females having higher overall IgG levels (p<0.001, Figure 2A). This difference is driven by females 
aged between 16 and 50 years (Figure 2A). Total IgG levels increase with age from birth (median 
46.2g/L in infants less than one year of age) to a plateau after 11 years of age (median 69.4g/L), 
Figure 2B. Since a univariate analysis of total IgG by sex indicated no difference, data were not 
separated by sex for this plot. 
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Figure 2. A. Median OD levels for TT IgG by sex and age group. B. Median total IgG (g/L) by age 
group. Vertical lines show IQR for each median data point. Total n=1,988. Figure 2A red lines 
represent median values for females, blue lines for males. Figure 2B shows data for males and 
females combined. IQR  ? interquartile range, OD  ? optical density.  
 
 
 In a multivariable linear regression model including TB disease status, being HIV-positive was 
associated with a decrease in all mycobacterial antibody levels studied (magnitude ranged from 
mean decrease of 0.240 OD (99% CI -0.361, -0.119) for IgG against Ag85A), to a mean decrease of 
0.446 OD (99% CI -0.640, -0.251) for IgM against Ag85A, all p<0.001, Table 2). Similarly, being in the 
upper tertile of HCMV IgG response was associated with a decrease in Ag85A, PPD and LAM IgG 
levels compared to being in the middle tertile: a mean decrease of 0.067 OD (99% CI -0.122, 0.012) 
for Ag85A IgG, 0.057 OD (99% CI -0.105, -0.009) for PPD IgG and 0.107 (99% CI -0.194, 0.019) for 
LAM IgG (all p<0.001, Table 2). While the direction of change was the same for CFP10/ESAT6 IgG and 
Ag85A IgM, the mean decrease associated with being in the upper tertile of HCMV IgG response was 
not sufficiently large to provide good evidence of a difference based upon our significance threshold 
(Table 2). The association between mycobacterial antibody levels and magnitude of HCMV IgG 
response was not linear (Figure 3): in comparison to the middle tertile of HCMV IgG response, the 
lowest tertile was also associated with a decrease in mycobacterial antibody levels. A mean decrease 
of 0.100 OD (99% CI -0.156, -0.044) p<0.001 was seen for CFP10/ESAT6 IgG and a mean decrease of 
0.104 OD (99% CI -0.205, -0.004) p=0.01 for Ag85A IgM. The direction of change was the same for 
the remaining mycobacterial antibodies (Table 2).  
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Figure 3. Adjusted mean OD change associated with HCMV tertile comparing to medium HCMV 
tertile as baseline. P values from multivariable linear regression model including age, quadratic age, 
sex, HIV and TB. Total n=1,956. Vertical lines show 99% CI for each mean OD change. OD  ? optical 
density, CI  ? confidence interval. (* model includes, age, quadratic age, sex, HIV and TB). 
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Table 2. Multivariable linear regression of variables with a potential influence on mycobacterial 
antibody levels. Values obtained using a multivariable regression model including age, quadratic 
age, sex, HIV and TB status, with p values and 99% CI (n=1,956). (CI  ? confidence interval, OD  ? 
optical density) 
 
    Ag85A IgG OD PPD IgG OD LAM IgG OD 
CFP10 ESAT 6 IgG 
OD Ag85A IgM OD 
Variable N (%) 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Coeff 
(99% CI) 
P 
value 
Sex 
 
    
  
    
  
    
Male 
978/1956 
(50.0%) baseline   baseline 
 
baseline   baseline 
 
baseline   
Female 
978/1956 
(50.0%) 
 -0.002  
(-0.045, 
0.041) 0.9 
 -0.002  
(-0.042,  
0.038) 0.91 
 -0.017  
(-0.099,  
0.064) 0.58 
 -0.025  
(-0.083,  
0.033) 0.27 
 -0.012  
(-0.103,  
0.079) 0.73 
HCMV Tertiles                     
HCMV 
low 
650/1956 
(33.2%) 
 -0.037  
(-0.090, 
0.016) 0.07 
 -0.009  
(-0.051,  
0.033) 0.57 
 -0.061  
(-0.151,  
0.030) 0.08 
 -0.100  
(-0.156,  
-0.044) <0.001 
 -0.104  
(-0.205,  
-0.004) 0.01 
HCMV 
medium 
650/1956 
(33.2%) baseline   baseline 
 
baseline   baseline 
 
baseline   
HCMV 
high 
656/1956 
(33.5%) 
 -0.067  
(-0.122,  
-0.012) <0.001 
 -0.057  
(-0.105,  
-0.009) <0.001 
 -0.107  
(-0.194,  
-0.019) <0.001 
 -0.015  
(-0.077,  
0.047) 0.54 
 -0.058  
(-0.152,  
0.035) 0.11 
HIV Status   
 
      
 
        
Negative 
1860/1956 
(95.1%) baseline 
 
baseline   baseline 
 
baseline   baseline   
Positive 
96/1956 
(4.9%) 
 -0.240  
(-0.361,  
-0.119) <0.001 
 -0.310  
(-0.422,  
-0.198) <0.001 
 -0.420  
(-0.586,  
-0.253) <0.001 
 -0.266  
(-0.409,  
-0.123) <0.001 
 -0.446  
(-0.640,  
-0.251) <0.001 
TB Status                     
Negative 
1929/1956 
(98.6%) baseline   baseline 
 
baseline   baseline 
 
baseline   
Positive 
27/1956 
(1.4%) 
 -0.101  
(-0.322, 
0.121) 0.24 
 -0.035  
(-0.217,  
0.147) 0.62 
 0.158  
(-0.107,  
0.424) 0.13 
0.175  
(-0.241,  
0.590) 0.28 
 -0.135  
(-0.609,  
0.340) 0.46 
 
Being a sputum-confirmed active TB case was not associated with any differences in any 
mycobacterial antibody level after adjusting for age, sex, HIV and HCMV level, although given that 
there were only 27 cases, there was limited statistical power to detect associations (Table 2). 
Coefficients of the effect of HIV and HCMV for each outcome measurement were similar for a model 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
including BCG instead of TB, and the magnitude of effect was not altered by adjusting for total IgG. 
Being BCG vaccinated was associated with a 0.115 OD increase in TT IgG (99% CI 0.004 - 0.227) 
p=0.01.  
 Table 3 shows that HIV positivity was associated with an increase in total levels of IgG (9.110 g/L 
(99% CI 3.735, 14.485), p<0.001). Being female was associated with an increase in TT of 0.272 OD 
(99% CI 0.188, 0.356, p<0.001) but no difference in total IgG levels. While being an active TB case 
was not associated with any differences in TT IgG, being a TB case was associated with a 5.8 g/L 
decrease (99% CI -13.298, 1.720) in total IgG however this was not significant (p=0.05). The 
magnitude of HCMV IgG response did not affect either total IgG levels or TT IgG response (Table 3).  
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Table 3. Multivariable linear regression of variables with a potential influence on Total IgG and TT-
specific IgG levels. Values obtained using a multivariable regression model including age, quadratic 
age, sex, HIV and TB status, with p value and 99% CI (n=1,956). CI  ? confidence interval, OD  ? optical 
density 
 
    Total IgG (g/L) TT IgG OD 
Variable N (%) Coeff (99% CI) 
P 
value Coeff (99% CI) 
P 
value 
Sex 
 
        
Male 978/1956 (50.0%) baseline   baseline   
Female 978/1956 (50.0%)  -0.326 (-2.350, 1.697) 0.68 0.272 (0.188, 0.356) <0.001 
HCMV Tertiles         
HCMV low 650/1956 (33.2%) 0.318 (-2.240, 2.877) 0.75 
 -0.090 (-0.187, 
0.008) 0.02 
HCMV 
medium 650/1956 (33.2%) baseline   baseline   
HCMV high 656/1956 (33.5%) 0.915 (-1.508, 3.338) 0.33 0.065 (-0.029, 0.159) 0.08 
HIV Status         
Negative 
1860/1956 
(95.1%) baseline   baseline   
Positive 96/1956 (4.9%) 9.110 (3.735, 14.485) <0.001 
 -0.172 (-0.357, 
0.012) 0.02 
TB Status         
Negative 
1929/1956 
(98.6%) baseline   baseline   
Positive 27/1956 (1.4%) 
 -5.789 (-13.298, 
1.720) 0.05 
 -0.081 (-0.328, 
0.165) 0.4 
 
Discussion 
In this study, we found that HIV infected individuals had decreased levels of all mycobacterial 
antibodies studied, with a concomitant increase in total IgG. We also found that individuals with the 
highest levels of HCMV IgG (indicative of highest exposure [26,27]),  had decreased levels of IgG 
specific for Ag85A, PPD and LAM, but had no corresponding change in total IgG levels. Previously our 
group has shown that TB patients have increased levels of HCMV IgG [17] and that HCMV positive 
infants (as measured by HCMV IFN-J ELISPOT) were at higher risk of progressing to active TB disease 
[13]. HCMV infection, being linked to poor long-term health outcomes [28,29] and large immune 
system subversion [16,30], may be acting to manipulate mycobacterial antibodies which may be 
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contributing to protective mechanisms against M.tb infection.  
 As has been seen previously [31], humoral responses against RD1 antigens ESAT6 or CFP10 
(mycobacterial proteins associated specifically with M.tb and not NTM or BCG) did not show an 
association with active TB cases in this study. Due to a lack of active TB case-finding in the GPC, it is 
likely that some of the individuals classed as TB negative here were latently infected with M.tb based 
on epidemiologic data on exposure in Uganda [32,33]. The finding that IgG responses to these M.tb-
specific antigens increase with age, following a similar pattern as other non-M.tb-specific 
mycobacterial antibodies, suggests that while NTM may be driving high responses of acute (IgM) and 
sustained (IgG) mycobacterial responses, exposure to M.tb itself cannot be ignored. 
 BCG vaccine status allocation in this study was by presence of scar, inspection of immunization 
card or verbal confirmation by parent of guardian. Despite issues with these methods [34], 
classification was thought to be robust due to the evidence of association of TT IgG with BCG 
indicating that people vaccinated for one Extended Programme of Immunization (EPI) schedule 
vaccine are more likely to have received other vaccinations upon accessing local health centers.  
 The magnitude of difference in mycobacterial antibodies seen due to HIV infection was far 
greater than due to either active TB disease or BCG vaccination. The lower levels of mycobacterial 
antibodies seen in individuals infected with HIV is accompanied by an increase in total IgG. The 
effect seen here points towards HIV infection having a mycobacteria-specific effect as opposed to a 
more general depression of all antibody levels, thereby confirming evidence seen previously in a 
much smaller number of patients in Italy [35]. It is known that HIV preferentially depletes TB-specific 
CD4 T cells [36]. Through their absence, TB-specific T cells would not provide signals to B cells in 
order for them to proliferate and differentiate into immunoglobulin-secreting plasma cells. As far as 
we are aware, the possible downstream humoral mechanism of HIV-associated TB-specific T cell 
depletion has not been investigated.  
 Here we see a similar association between the highest levels of HCMV IgG, and decreased levels 
of some mycobacterial antibodies. This is not accompanied by a decrease in total IgG or TT IgG. As a 
human herpes virus, HCMV persists in a variety of cell types in a dormant state and is transmitted 
through body fluids [37]. Infection is not normally associated with symptomatic disease, however it 
poses a huge burden on the immune system, with maintenance of up to 30% of both CD4 and CD8 
circulating memory T cells being specific to HCMV [38]. The virus is a significant factor in immune 
variation [16], immunosenescence [15], and causes immune activation [39], including non-specific 
polyclonal B-cell activation and proliferation [40].  
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 In this study, we see decreased mycobacterial antibody levels at both HCMV IgG extremes 
among HCMV seropositive individuals. Evidence of HCMV effect on vaccine responses exists, 
showing both a detrimental impact of HCMV infection [41,42] and a positive,  ?ĂĚũƵǀĂŶƚŝŶŐ ? ?ĞĨĨĞĐƚŽĨ
HCMV on vaccine-induced antibody responses in humans [43]. Given reports that cellular responses 
to heterologous virus challenge in mice may depend on the initial viral dose of HCMV [44,45] the 
lack of a linear response between HCMV IgG and mycobacterial antibody levels seen in this study 
may also be indicative of different effects at different HCMV exposure levels. PBMC samples were 
not available from this cohort for us to determine if magnitude of HCMV IgG level had a similar 
impact on the mycobacteria-specific cellular immune response.  However, it is likely that cellular 
immunity is also impacted by HCMV given that HCMV has been shown to affect both humoral and 
cell mediated immune responses to vaccine antigens [46,47].  
 Before the widespread use of highly active anti-retrovirals (HAART), HCMV/HIV co-infection saw 
HCMV as an important cause of severe non-AIDS events, including death, in HIV-infected individuals 
[48]. High levels of HCMV IgG, caused by repeated reactivation or reinfection events, are associated 
with higher all-cause mortality [49] and lower CD4 cell count, with accompanying worse response to 
anti-retrovirals [50]. Despite literature describing HCMV-induced B cell activation [40,51,52], in this 
study we saw no relationship between HCMV exposure and increased levels of total IgG. We do 
however see a trend towards decreased mycobacterial antibody response in individuals with very 
high HCMV IgG responses after adjusting for HIV infection. Considering the risk of developing active 
TB disease increases over 20 times in individuals with HIV [53], it is likely that any added effect of 
HCMV would be masked. The mycobacterial antibody-specific decrease seen with both HIV infection 
and, independently, in the highest tertile of HCMV exposure, may be indicative of a functional, 
protective role of mycobacterial-specific antibodies which are independently decreased by HIV and 
high levels of exposure to HCMV.  
 In summary, both HIV infection and high levels of HCMV IgG were both associated with 
decreases in mycobacterial antibody levels. Given this novel finding of effect of HCMV exposure on 
mycobacterial antibody levels, investigation of magnitude of HCMV may be important in future TB 
clinical trials to understand the immune environment, independently of HIV infection status. In 
addition to quantification of antibody levels, we believe that it will be important to measure HCMV 
effect on mycobacteria-specific cellular responses. A more nuanced understanding of the quality, as 
well as the quantity, of the mycobacterial antibodies elicited, in terms of antibody class, subtype and 
avidity may help to shed light upon a potential mechanism by which they might confer protection to 
host cells.  
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 Due to insufficient volumes of sera, we were unable to investigate HCMV viral load in serum 
samples to ascertain whether active infection at point of blood draw was associated with any of the 
measurements taken for this study. Despite this, we believe that use of HCMV-specific IgG is a 
robust a measure of cumulative exposure. As previously mentioned, active TB case finding is not 
ĐĂƌƌŝĞĚŽƵƚǁŝƚŚŝŶƚŚĞ'WĂŶĚƚŚĞƌĞĨŽƌĞǁĞĐĂŶŶŽƚďĞƐƵƌĞƚŚĂƚƐŽŵĞŝŶĚŝǀŝĚƵĂůƐĂŶĂůǇƐĞĚĂƐ ?ŶŽŶ-
d ?ĂƌĞŶŽƚůĂƚĞŶƚůǇŝŶĨĞĐƚĞĚ ?PBMC samples were not available from this cohort for us to determine 
if HCMV had a similar impact on the mycobacterial cellular immune response.   
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